Molecular Formula | C20H19NO5 |
Molar Mass | 353.37 |
Density | 1.432 |
Boling Point | 580.8±40.0 °C(Predicted) |
pKa | 2.02±0.10(Predicted) |
Storage Condition | Store at RT |
In vivo study | LY341495 (0.3, 1, and 3 mg/kg, i.p.) displays a lower level of discrimination in rats. LY341495 (3.0 mg/kg) decreases Dvl-2, pGSK-3α/β and β-catenin protein levels but Dvl-1, Dvl-3 and GSK-3α/β are unaffected in both the PFC and STR. LY341495 has the generally the opposite effect following acute and chronic administration compared to mGlu2/3 agonist, LY379268. LY341495 (3 mg/kg, i.p., 2.5 h) -induced c-Fos expression is not altered in either KO brain. LY341495 is almost inactive in the central extended amygdala [central nucleus of the amygdala, lateral (CeL) and bed nucleus of the stria terminalis, laterodorsal (BSTLD)] in mGluR3-KO mice. |
1mg | 5mg | 10mg | |
---|---|---|---|
1 mM | 2.83 ml | 14.149 ml | 28.298 ml |
5 mM | 0.566 ml | 2.83 ml | 5.66 ml |
10 mM | 0.283 ml | 1.415 ml | 2.83 ml |
5 mM | 0.057 ml | 0.283 ml | 0.566 ml |
biological activity | LY341495 is a metabotropic glutamate receptor (mGluR) antagonist for mGlu2,mGlu3,mGlu1a,mGlu5a, the IC50 of mGlu8,mGlu7 and mGlu4 receptors are 21 nM,14 nM,7.8 μm, 8.2 μm, 170 nM,990 nM and 22 μm, respectively. |